October 10, 2019 / 11:55 PM / 5 days ago

SoftBank-backed Vir Biotechnology raises $143 mln in U.S. IPO

NEW YORK, Oct 10 (Reuters) - Vir Biotechnology priced its initial public offering (IPO) at $20 a share on Thursday, at the bottom end of expectations, a fresh blow for SoftBank Group Corp’s Vision Fund, owner of 21% in the infectious disease researcher.

San Francisco-based Vir raised $142.9 million having previously set a price range of $20-$22 per share. The IPO valued Vir at $2.2 billion.

Reporting by Joshua Franklin in New York; Editing by Tom Hogue

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below